A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV).
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Candesartan cilexetil
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms OLMEBNP
- Sponsors Daiichi Sankyo Europe
- 31 Aug 2018 Biomarkers information updated
- 06 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Sep 2008 Actual start date added (Jun 2008) as reported by ClinicalTrials.gov.